别名 G protein-coupled receptor 109A、G-protein coupled receptor 109A、G-protein coupled receptor HM74A + [10] |
简介 Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide. |
靶点 |
作用机制 NIACR1激动剂 |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 意大利 |
首次获批日期1985-01-01 |
作用机制 HCAR3激动剂 [+1] |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期1956-11-01 |
作用机制 HCAR3激动剂 [+1] |
在研机构- |
原研机构- |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-10-01 |
申办/合作机构 Indiana University [+1] |
开始日期2024-08-29 |
申办/合作机构 |
开始日期2024-08-10 |
申办/合作机构 |